|
ÓÖÒ»Åúҽѧ¿ÆÑгÏÐ۸¼þ±»Í¨±¨£¡À´Ô´£ü¿Æ¼¼½ÌÓý˾ 10ÔÂ15ÈÕ£¬**ÎÀ½¡Î¯¿Æ¼¼½ÌÓý˾¹«²¼ÁË16Æðҽѧ¿ÆÑгÏÐ۸¼þµ÷²é´¦Àí½á¹û¡£µ÷²é´¦Àí½á¹û×ªÔØÈçÏ£º 01.ºþ±±Ê¡¶÷Ê©ÍÁ¼Ò×åÃç×å×ÔÖÎÖÝÖÐÐÄÒ½ÔºÐìÑÞ»ªÎªÍ¨Ñ¶×÷Õߣ¬ÖÜÇïæÂΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°MiR-221 affects proliferation and apoptosis of gastric cancer cells through targeting SOCS3¡±¾²é£¬¸ÃÂÛÎÄ**×÷ÕßÖÜÇïæÂ´æÔÚÂòÂôÊý¾Ý¡¢±àÔìÑо¿¹ý³ÌµÄѧÊõ²»¶ËÐÐΪ£¬Í¨Ñ¶×÷ÕßÐìÑÞ»ª´æÔÚ²»Õýµ±ÊðÃûµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷ÕßÖÜÇïæÂ£º¿ÆÑгÏÐŽëÃã̸»°£»ÔÚÒ½ÔºÖÜ»áÉÏͨ±¨ÅúÆÀ£»ÎåÄêÄÚ²»µÃ½úÖ°½úÉý£¬Í˳ö¶÷Ê©ÖÝÖÐÐÄÒ½ÔºÇàÄêÈ˲ųɳ¤¹¤³Ì£¬Í˻شËÎÄÕÂËùµÃÒ½Ôº½±Àø£»³·¸å£»È¡Ïû±¾Äê¶ÈÆÀÏȱíÄ£×ʸñ¡£ 2.¶ÔͨѶ×÷ÕßÐìÑÞ»ª£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Ò»ÄêÄÚ²»µÃ½úÖ°½úÉý£¬È¡Ïû±¾Äê¶ÈÆÀÏȱíÄ£×ʸñ¡£ 02.ɽ¶«Ê¡ÁÙÒÊÊÐÖÐÐÄÒ½ÔººîÊËÕñΪ**×÷Õß¡¢³Ì×ÓÃ÷ΪͨѶ×÷Õß·¢±íÂÛÎÄ¡°Ailanthone exerts an antitumor function on thedevelopment of human lung cancer by upregulating microRNA©195¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôµÄѧÊõ²»¶ËÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃ**×÷ÕßÖªÇé֪ͨ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷ÕߺîÊËÕñ£º¿ÆÑгÏÐŽëÃã̸»°£¬Ôð³ÉÆäд³öÊéÃæ¼ì²é£»È«ÔºÍ¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä6ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ6ÄꣻҪÇóÆä30ÌìÄÚÁªÏµÔÓÖ¾Éç³·¸å£»·£¿î5000Ôª¡£ 2.¶ÔͨѶ×÷Õß³Ì×ÓÃ÷£º¿ÆÑгÏÐŽëÃã̸»°£¬Ôð³ÉÆäд³öÊéÃæ¼ì²é£»È«ÔºÍ¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä1ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1ÄꣻҪÇóÆä30ÌìÄÚÁªÏµÔÓÖ¾Éç³·¸å¡£ 3.¶ÔÆäËû×÷ÕßÍõÎÄÁá¡¢ÍõÏò¶«¡¢ÎäÓñ±ø£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚͨ±¨ÅúÆÀ¡£ 03.ɽ¶«Ê¡ÁÙÒÊÊÐÖÐÐÄÒ½Ôº¼ÖÊçÓñΪ**×÷Õß¡¢ÕÅ·ÉΪͨѶ×÷Õß·¢±íÂÛÎÄ¡°MicroRNA-210 protects against periodontitis through targeting HIF-3¦Áand inhibiting p38MAPK/NF-¦ÊB pathway¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôµÄѧÊõ²»¶ËÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃ**×÷ÕßÖªÇé֪ͨ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷Õß¼ÖÊçÓñ£º¿ÆÑгÏÐŽëÃã̸»°£¬Ôð³ÉÆäд³öÊéÃæ¼ì²é£»È«ÔºÍ¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5ÄꣻҪÇóÆä30ÌìÄÚÁªÏµÔÓÖ¾Éç³·¸å£»·£¿î5000Ôª¡£ 2.¶ÔͨѶ×÷ÕßÕÅ·É£º¿ÆÑгÏÐŽëÃã̸»°£¬Ôð³ÉÆäд³öÊéÃæ¼ì²é£»È«ÔºÍ¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä1ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1ÄꣻҪÇóÆä30ÌìÄÚÁªÏµÔÓÖ¾Éç³·¸å¡£ 3.¶ÔÆäËû×÷ÕßÑîÎ÷ÃÀ¡¢ÑîÎ÷ÈÙ£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚͨ±¨ÅúÆÀ¡£ 04.ɽ¶«Ê¡ÁÙÒÊÊÐÖÐÐÄÒ½ÔºÆÝµÂ·åΪ**×÷Õß¡¢Óڷ绪ΪͨѶ×÷Õß·¢±íÂÛÎÄ¡°Knockdown of lncRNA-H19 inhibits cell viability,migration and invasion T while promotes apoptosis via microRNA-143/RUNX2 axis in retinoblastoma¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôµÄѧÊõ²»¶ËÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃ**×÷ÕßÖªÇé֪ͨ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷ÕßÆÝµÂ·å£º¿ÆÑгÏÐŽëÃã̸»°£¬Ôð³ÉÆäд³öÊéÃæ¼ì²é£»È«ÔºÍ¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·ÏúÆäÀûÓÿÆÑÐʧÐÅÐÐΪ»ñµÃ¸±Ö÷ÈÎҽʦְ³Æ×ʸñ£»ÒªÇóÆä30ÌìÄÚÁªÏµÔÓÖ¾Éç³·¸å£»·£¿î5000Ôª¡£ 2.¶ÔͨѶ×÷ÕßÓڷ绪£º¿ÆÑгÏÐŽëÃã̸»°£¬Ôð³ÉÆäд³öÊéÃæ¼ì²é£»È«ÔºÍ¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î¡£È¡ÏûÆä2ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä2ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ2ÄꣻҪÇóÆä30ÌìÄÚÁªÏµÔÓÖ¾Éç³·¸å¡£ 3.ÆäËû×÷ÕßÍõÃ÷Ã÷£ºÎªÇൺÊгÇÑôÇøÈËÃñÒ½ÔºÖ°¹¤£¬ÇൺÊгÇÑôÇøÈËÃñÒ½Ôº¸øÓèÍõÃ÷Ã÷£º¿ÆÑгÏÐŽëÃã̸»°£¬È¡Ïû2020Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£ 05.ɽ¶«Ê¡ÁÙÒÊÊÐÖÐÐÄÒ½Ôº**×÷ÕßÐ콨¡¢ÕÔÖ¾¾êΪͨѶ×÷Õß·¢±íÂÛÎÄ¡°Ras-ERK1/2signaling participates in the progression of gastric cancer through repressing Aurora-B-mediated H1.4 phoshorylation at Ser27¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôµÄѧÊõ²»¶ËÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃ**×÷ÕßÖªÇé֪ͨ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷ÕßÐ콨£º¿ÆÑгÏÐŽëÃã̸»°£¬Ôð³ÉÆäд³öÊéÃæ¼ì²é£»È«ÔºÍ¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5ÄꣻҪÇóÆä30ÌìÄÚÁªÏµÔÓÖ¾Éç³·¸å£»·£¿î5000Ôª¡£ 2.¶ÔͨѶ×÷ÕßÕÔÖ¾¾ê£º¿ÆÑгÏÐŽëÃã̸»°£¬Ôð³ÉÆäд³öÊéÃæ¼ì²é£»È«ÔºÍ¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä1ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1ÄꣻҪÇóÆä30ÌìÄÚÁªÏµÔÓÖ¾Éç³·¸å¡£ 3.¶ÔÆäËû×÷ÕßÌï·å¡¢³ÂÐËÌï¡¢ÁõÕ×ϼ¡¢Î䴫ϼ£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚͨ±¨ÅúÆÀ¡£ 06.ɽ¶«Ê¡ÇൺÊеÚÁùÈËÃñÒ½ÔºËïÊ÷Â×ΪͨѶ×÷Õߣ¬ÓÚÑ©¡¢ÍõÓñΪ²¢ÁÐ**×÷Õß·¢±íµÄÂÛÎÄ¡°Geniposide plays anti-tumor effects by down-regulation of microRNA-224 in HepG2 and Huh7 cell lines¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£ÇൺÊеÚÁùÈËÃñÒ½Ôº¶ÔͨѶ×÷ÕßËïÊ÷Âס¢**×÷ÕßÓÚÑ©¼°²¢ÁÐ**×÷ÕßÍõÓñ×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬È¡ÏûÎåÄêÄÚÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍרҵ¼¼ÊõÖ°Îñ½úÉýµÈ×ʸñ£¬È¡Ïûѧ»á¡¢Ð»á¡¢Ñо¿»áµÈѧÊõÍÅÌåÒÔ¼°Ñ§Êõ¡¢Ñ§Î»Î¯Ô±»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬È¡ÏûÎåÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬³·¸å¡£ 07.ɽ¶«Ê¡ÇൺÊк£´ÈÒ½ÁƼ¯ÍÅÇúÂüÇàΪͨѶ×÷Õß¡¢ÕÅϲ¾üΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Angelica polysaccharide alleviates oxidative response damage in HaCaT cells through up-regulation of miR-126¡±£¬¾²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³Ì¡¢²»µ±ÊðÃûµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷ÕßÕÅϲ¾ü¡¢Í¨Ñ¶×÷ÕßÇúÂüÇࣺ¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚ¹«¿ªÍ¨±¨ÅúÆÀ£¬Á¢¼´ÁªÏµÔÓÖ¾Éç³·¸åÉæÊÂÂÛÎÄ£¬È¡ÏûÎåÄêÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬È¡ÏûÎåÄêרҵ¼¼ÊõÖ°Îñ½úÉý×ʸñ¡£ 2.¶ÔµÚ¶þ×÷ÕßѦºì¡¢µÚÈý×÷ÕßÖÜÆ¼¡¢µÚËÄ×÷ÕßÁõÀö¡¢µÚÎå×÷ÕßÓÚ¾§¡¢µÚÁù×÷Õß´úÅó·É£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚ¹«¿ªÍ¨±¨ÅúÆÀ£¬È¡ÏûÒ»ÄêÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬È¡ÏûÒ»Äêרҵ¼¼ÊõÖ°Îñ½úÉý×ʸñ¡£ 08.ɽ¶«Ê¡ÇൺÊк£´ÈÒ½ÁƼ¯ÍÅÍõº£¾²ÎªÍ¨Ñ¶×÷Õß¡¢×Þ¬BΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Euxanthone Inhibits Glycolysis and Triggers Mitochondria-Mediated Apoptosis by Targeting Hexokinase 2 in Epithelial Ovarian Cancer¡±£¬¾²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³Ì¡¢²»µ±ÊðÃûµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷Õß×Þ¬B£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚ¹«¿ªÍ¨±¨ÅúÆÀ£¬Á¢¼´ÁªÏµÔÓÖ¾Éç³·¸åÉæÊÂÂÛÎÄ£¬ÊջؿÆÑн±Àø£¬È¡ÏûÎåÄêÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬È¡ÏûÎåÄêרҵ¼¼ÊõÖ°Îñ½úÉý×ʸñ£¬È¡ÏûÓÉ´Ë»ñµÃµÄ¸±¸ß¼¶Ö°³Æ¡£ 2.¶ÔͨѶ×÷ÕßÍõº£¾²£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚ¹«¿ªÍ¨±¨ÅúÆÀ£¬Á¢¼´ÁªÏµÔÓÖ¾Éç³·¸åÉæÊÂÂÛÎÄ£¬È¡ÏûÎåÄêÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬È¡ÏûÎåÄêרҵ¼¼ÊõÖ°Îñ½úÉý×ʸñ¡£ 3.¶ÔµÚ¶þ×÷ÕßÍõÑÇ÷¡¢µÚÎå×÷ÕßÖ£ÎĽ¨¡¢µÚÁù×÷Õ߸ßÜ磺¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚ¹«¿ªÍ¨±¨ÅúÆÀ£¬È¡ÏûÒ»ÄêÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬È¡ÏûÒ»Äêרҵ¼¼ÊõÖ°Îñ½úÉý×ʸñ¡£ 4.¶ÔµÚÈý×÷ÕßÁõÃ÷æ·£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚ¹«¿ªÍ¨±¨ÅúÆÀ£¬È¡ÏûÒ»ÄêÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬È¡ÏûÒ»Äêרҵ¼¼ÊõÖ°Îñ½úÉý×ʸñ£¬È¡ÏûÖм¶Ö°³Æ¡£ 09.ɽ¶«Ê¡ÇൺÊÐÖÐÐÄÒ½ÔºÀèÓ¢ºÀΪͨѶ×÷Õߣ¬ÑîТÁ¼**×÷Õß·¢±íµÄÂÛÎÄ¡°Baicalein restrains proliferation,migration,and invasion of human malignant melanoma cells by down-regulating colon cancer associated transcr1pt-1¡±£¬¾²é£¬Ïµ´æÔÚ´Û¸ÄʵÑéÊý¾ÝµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÀèÓ¢ºÀ£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚ¹«¿ªÍ¨±¨ÅúÆÀ£¬×·»ØÎÄÕ½±Àø²¢ÒªÇóÆäÖ÷¶¯ÏòÔÓÖ¾Éç³·»ØÎÄÕ£¬È¡ÏûÆäÎåÄêÉ걨¿ÆÑÐÏîÄ¿¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍÖ°³Æ½úÉý×ʸñ¡£ 2.¶Ô**×÷ÕßÑîТÁ¼£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚ¹«¿ªÍ¨±¨ÅúÆÀ£¬È¡ÏûÆäÎåÄêÉ걨¿ÆÑÐÏîÄ¿¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍÖ°³Æ½úÉý×ʸñ¡£ 3.¶ÔµÚ¶þ×÷Õß½ª½ò½Ü¡¢µÚÈý×÷ÕßÕÅ´ºÑÞ£º¿ÆÑгÏÐŽëÃã̸»°£¬ÔºÄÚ¹«¿ªÍ¨±¨ÅúÆÀ£¬È¡ÏûÆä¶þÄêÉ걨¿ÆÑÐÏîÄ¿¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍÖ°³Æ½úÉý×ʸñ¡£ 10.ºÓÄÏÊ¡ÈËÃñÒ½ÔºÑîÖ¾¸ÕΪͨѶ×÷Õß¡¢ÀîÏþÁÁΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Silence of MEG3 intensifies lipopolysaccharide-stimulated damage of human lung cells through modulating miR-4262¡±£¬¾²é£¬Ïµ´æÔÚµÚÈý·½»ú¹¹ÌṩʵÑéͼƬºÍʵÑéÊý¾Ý£¨ÂòÂôÊý¾Ý£©µÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷ÕßÀîÏþÁÁ£º¿ÆÑгÏÐŽëÃã̸»°£¬È«Ôº¹«¿ªÍ¨±¨ÅúÆÀ£¬È¡ÏûÆÀÓÅÆÀÏÈ×ʸñ5Ä꣬ȡÏûÉ걨Ñо¿Éúµ¼Ê¦×ʸñ»òÔÝÍ£ÕÐÊÕÑо¿Éú5Ä꣬ȡÏûÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍרҵ¼¼ÊõÖ°Îñ½úÉýµÈ×ʸñ5Ä꣬³·¸å¡£ 2.¶ÔͨѶ×÷ÕßÑîÖ¾¸Õ£º¿ÆÑгÏÐŽëÃã̸»°£¬È¡Ïûµ±ÄêÆÀÓÅÆÀÏÈ×ʸñ¡£ 11.ºÓÄÏÊ¡ÈËÃñÒ½Ôº´ÞÊçæµÎªÍ¨Ñ¶×÷Õß¡¢ÀîÁáΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Baicalin relieves TNF-alpha-evoked injury in human aortic endothelial cells by up-regulation of miR-145¡±£¬¾²é£¬Ïµ´æÔÚµÚÈý·½»ú¹¹ÌṩʵÑéͼƬºÍʵÑéÊý¾Ý£¨ÂòÂôÊý¾Ý£©²¢´úΪͶ¸åµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷ÕßÀîÁ᣺¿ÆÑгÏÐŽëÃã̸»°£¬È«Ôº¹«¿ªÍ¨±¨ÅúÆÀ£¬È¡ÏûÆÀÓÅÆÀÏÈ×ʸñ5Ä꣬ȡÏûÉ걨Ñо¿Éúµ¼Ê¦×ʸñ»òÔÝÍ£ÕÐÊÕÑо¿Éú5Ä꣬ȡÏûÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍרҵ¼¼ÊõÖ°Îñ½úÉýµÈ×ʸñ5Ä꣬³·¸å¡£ 2.¶ÔͨѶ×÷Õß´ÞÊçæµ£º¿ÆÑгÏÐŽëÃã̸»°£¬È¡Ïûµ±ÄêÆÀÓÅÆÀÏÈ×ʸñ¡£ 3.¶ÔÆäËûÏà¹Ø×÷ÕßÁõÃô¡¢ºÕÁ¬Âü¡¢Íõɺɺ£º¿ÆÑгÏÐŽëÃã̸»°¡£ 12.½ËÕÊ¡ÄϾ©Ò½¿Æ´óѧÔÚְרҵѧλÑо¿ÉúÉò·ÉΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Amentoflavone Promotes Apoptosis in Non-small Cell Lung Cancer by Modulating Cancerous Inhibitor of PP2A¡±£¬¾²é£¬Ïµ´æÔÚαÔì¼°´Û¸ÄÊý¾Ý¡¢Î´¾Í¨Ñ¶×÷Õß¼°ÆäËû×÷ÕßͬÒâÊðÆäÃû¡¢Î¯ÍеÚÈý·½´úͶÂÛÎĵÄѧÊõ²»¶ËÐÐΪ¡£ 1.ÄϾ©Ò½¿Æ´óѧ¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦Àí£¬³·ÏúÉò·É²©Ê¿Ñ§Î»£¬ÔÝÍ£**¸½ÊôҽԺͨѶ×÷Õß³ÂÒà½Ñо¿ÉúÕÐÉú×ʸñ3Äê¡£ 2.**×÷Õß¹¤×÷µ¥Î»½ÒõÊÐÈËÃñÒ½Ôº¸øÓèÉò·ÉÐÐÕþ¾¯¸æ´¦·Ö£¬È«ÔºÍ¨±¨ÅúÆÀ£¬5ÄêÄÚÈ¡ÏûÉêÇë»òÉ걨¸÷Àà¿Æ¼¼¼Æ»®ÏîÄ¿¡¢È˲ųƺÅ×ʸñ£¬È¡Ïûרҵ¼¼ÊõÖ°Îñ½úÉý5Äê¡£ 13.½ËÕÊ¡½ÒõÊÐÈËÃñÒ½Ôº¡¢ÄϾ©Ò½¿Æ´óѧ¸½ÊôÒÝ·òÒ½ÔºÔÚÖ°²©Ê¿Ñо¿Éú·½ÃúΪ**×÷Õߣ¬·¢±íÓÚTHE ANATOMICAL RECORDÔÓÖ¾µÄÂÛÎÄ¡°Alpinumisoflavone Inhibits Tumor Growth and Metastasis in Papillary Thyroid Cancer via Upregulating miR©141©3p¡±£¬¾²é£¬ÏµÓÉ**×÷Õß·½Ãú˽×ÔͶ¸å£¬´æÔÚαÔìÓÊÏä¡¢²»µ±ÊðÃûµÈѧÊõ²»¶ËÐÐΪ¡£ ½ÒõÊÐÈËÃñÒ½Ôº¼°ÄϾ©Ò½¿Æ´óѧ¼°¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º³·Ïú**×÷Õß·½Ãú²©Ê¿Ñ§Î»£¬È¡ÏûÆäÉ걨¸÷¼¶¿Æ¼¼¼Æ»®ÏîÄ¿¡¢×¨Òµ¼¼ÊõÖ°³Æ½úÉýµÈ×ʸñ8Äê£¨Éæ¼°ÆäËûѧÊõ²»¶ËÐÐΪ£¬ºÏ²¢´¦·££©£»ÔÝÍ£µ¼Ê¦ÁõìÏרҵѧλ²©Ê¿Ñо¿ÉúÕÐÊÕ×ʸñ3Äê¡£ 14.½ËÕÊ¡ÎÞÎýÊи¾Ó×±£½¡ÔºÔ¼ìÑé¿ÆÐí·ÉΪͨѶ×÷Õß¡¢ÎÞÎýÊÐÖÐÒ½Ò½Ôº¶¡ÖÒÑôΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Physcion 8-O-¦Â-glucopyranoside prevents hypoxia-induced epithelial-mesenchymal transition in colorectal cancer HCT116 cells by modulating EMMPRIN¡±£¬¾²é£¬Ïµ´æÔÚίÍеÚÈý·½´úд¡¢´úͶµÄѧÊõ²»¶ËÐÐΪ¡£Ðí·ÉÓÚ2017ÄêÒòÆäËû¾¼Ã°¸¼þ±»Åд¦ÈýÄêÓÐÆÚͽÐÌ£¬ÎÞÎýÊи¾Ó×±£½¡ÔºÓÚ2018Ä꽫Æä¿ª³ý´¦·Ö¡£ÎÞÎýÊÐÖÐÒ½Ò½Ôº¶Ô¶¡ÖÒÑô×ö³öÈçÏ´¦Àí£º¿ÆÑнëÃã̸»°£¬×·»Ø·¢·ÅµÄ¿ÆÑн±Àø£¬È¡Ïû¸÷¼¶¸÷Àà¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¸÷ÀàÈ˲ųƺźÍרҵ¼¼ÊõÖ°Îñ½úÉýµÈ×ʸñ5Äê¡£ 15.ÄÏͨÊÐÖÐÒ½ÔºÓ÷º£ÖÒ×÷ΪͨѶ×÷Õß¡¢ÄÏͨÊÐÖ×ÁöҽԺФ´ººìΪ¹²Í¬Í¨Ñ¶×÷Õߣ¬ÄÏͨÊÐÖÐÒ½Ôº²ÜºìÑÞΪ**×÷Õߣ¬·¢±íµÄÂÛÎÄ¡°miR-129 reduces CDDP resistance in gastric cancer cells by inhibiting MAPK3¡±£¬¾²é£¬Ð¤´ººì×÷Ϊ¹²Í¬Í¨Ñ¶×÷Õߣ¬´æÔÚÎ¥¹æÊ¹ÓÃÁË»ù½ðºÅ¡°No.MS12017017-4¡±¡¢´Û¸ÄÊý¾ÝµÄѧÊõ²»¶ËÐÐΪ¡£ 1.ÄÏͨÊÐÖ×ÁöÒ½Ôº¶ÔͨѶ×÷ÕßФ´ººì×÷³öÈçÏ´¦Àí£ºÔÝÍ£É걨²ÆÕþ×ÊÖú¿Æ¼¼¼Æ»®£¨×¨Ïî¡¢»ù½ðµÈ£©ÏîÄ¿µÈ×ʸñ8Ä꣬׷»ØÏà¹ØÂÛÎĽ±Àø£¬Í¨±¨ÅúÆÀ¡£ 2.ÄÏͨÊÐÖÐÒ½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º £¨1£©¶ÔͨѶ×÷ÕßÓ÷º£ÖÒ£ºÍ¨±¨ÅúÆÀ£¬³·¸å£¬È¡ÏûÉ걨²ÆÕþ×ÊÖú¿Æ¼¼¼Æ»®£¨×¨Ïî¡¢»ù½ðµÈ£©ÏîÄ¿µÈ×ʸñ8Äê£¨Ç£ÉæÆäËûÂÛÎÄÔì¼Ù£¬ºÏ²¢´¦·££©£¬×·»ØÂÛÎÄÒ»´ÎÐÔ½±½ð£¬Õû¸ÄºÍ¼ÓǿѧÊõÍŶӹÜÀí¡¢È¡ÏûѧÊõίԱ»áίԱ×ʸñ¡£ £¨2£©¶Ô**×÷Õ߲ܺìÑÞ£ºÍ¨±¨ÅúÆÀ£¬³·¸å£¬×·»ØÂÛÎÄÒ»´ÎÐÔ½±½ð£¬¿ÆÑгÏÐŽëÃã̸»°£¬Õû¸ÄºÍ¼ÓǿѧÊõÍŶӹÜÀí¡¢È¡ÏûѧÊõίԱ»áίԱ×ʸñ¡£ 16.Öйúҽѧ¿ÆÑ§Ôº±±¾©ÐºÍÒ½Ôº´ÞÓñÉÐΪͨѶ×÷Õß¡¢ÐìÏþ»ÔΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°MicroRNA-1246 inhibits cell invasion and epithelial mesenchymal transition process by targeting CXCR4 in lung cancer cells¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄͼƬÔì¼ÙµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1¡¢¶ÔͨѶ×÷Õß´ÞÓñÉУºÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®£¨×¨Ïî¡¢»ù½ðµÈ£©ÏîÄ¿×ʸñ5Ä꣬ȡÏû½úÉýÖ°ÎñÖ°³Æ×ʸñ3Ä꣬¼ÇÈë¿ÆÑгÏÐÅÐÅÓÃÐÅϢϵͳ£¬¿ÆÑгÏÐŽëÃã̸»°µÄ´¦·£¡£ 2¡¢¶Ô**×÷ÕßÐìÏþ»Ô£ºÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®£¨×¨Ïî¡¢»ù½ðµÈ£©ÏîÄ¿×ʸñ5Ä꣬ȡÏû½úÉýÖ°ÎñÖ°³Æ×ʸñ3Ä꣬¼ÇÈë¿ÆÑгÏÐÅÐÅÓÃÐÅϢϵͳ£¬¾¯¸æµÄ´¦·£¡£ END ±à¼£ºÐ¡»Æ |